LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq:FRLN) today announced that on May 31, 2022, the Company granted its newly hired Chief Financial Officer, Paul Schneider, and six other newly hired employees non-statutory options to purchase an aggregate of 270,000 and 191,850 of the Company’s ordinary shares, respectively.
Freeline Announces May 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here